- Home
- CAAS vs BMEA Comparison
CAAS vs BMEA Comparison
Compare CAAS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAS
- BMEA
- Stock Information
- Founded
- CAAS N/A
- BMEA 2017
- Country
- CAAS China
- BMEA United States
- Employees
- CAAS N/A
- BMEA N/A
- Industry
- CAAS Auto Parts:O.E.M.
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CAAS Consumer Discretionary
- BMEA Health Care
- Exchange
- CAAS Nasdaq
- BMEA Nasdaq
- Market Cap
- CAAS 131.8M
- BMEA 114.3M
- IPO Year
- CAAS N/A
- BMEA 2021
- Fundamental
- Price
- CAAS $4.60
- BMEA $1.96
- Analyst Decision
- CAAS
- BMEA Strong Buy
- Analyst Count
- CAAS 0
- BMEA 10
- Target Price
- CAAS N/A
- BMEA $15.70
- AVG Volume (30 Days)
- CAAS 63.5K
- BMEA 614.1K
- Earning Date
- CAAS 11-12-2025
- BMEA 10-28-2025
- Dividend Yield
- CAAS N/A
- BMEA N/A
- EPS Growth
- CAAS N/A
- BMEA N/A
- EPS
- CAAS 0.97
- BMEA N/A
- Revenue
- CAAS $696,272,000.00
- BMEA N/A
- Revenue This Year
- CAAS N/A
- BMEA N/A
- Revenue Next Year
- CAAS N/A
- BMEA N/A
- P/E Ratio
- CAAS $4.61
- BMEA N/A
- Revenue Growth
- CAAS 17.08
- BMEA N/A
- 52 Week Low
- CAAS $3.46
- BMEA $1.29
- 52 Week High
- CAAS $5.37
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- CAAS 61.41
- BMEA 55.83
- Support Level
- CAAS $4.31
- BMEA $1.86
- Resistance Level
- CAAS $4.14
- BMEA $2.11
- Average True Range (ATR)
- CAAS 0.22
- BMEA 0.12
- MACD
- CAAS 0.01
- BMEA 0.01
- Stochastic Oscillator
- CAAS 74.32
- BMEA 56.38
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.